Meeting
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
Authors
Melissa Lynne Johnson
Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN
Melissa Lynne Johnson , Vincent A. Miller , Suraj Patel , Yumin Zhao , Li Cheng , Siraj Mahamed Ali , Michael Wooten , Davey B. Daniel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05493501
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9153)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9153
Abstract #
TPS9153
Poster Bd #
134a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2019 ASCO Annual Meeting
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
First Author: Caicun Zhou
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2024 ASCO Annual Meeting
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
First Author: Nobuaki Mamesaya